2160 Stock Overview
Engages in the research, development, manufacture, and sale of pharmaceutical drugs in Japan and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 5/6 |
| Past Performance | 1/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
GNI Group Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | JP¥2,486.00 |
| 52 Week High | JP¥3,970.00 |
| 52 Week Low | JP¥1,469.00 |
| Beta | 1.22 |
| 1 Month Change | 37.58% |
| 3 Month Change | -24.89% |
| 1 Year Change | 1.39% |
| 3 Year Change | 132.55% |
| 5 Year Change | 36.89% |
| Change since IPO | 767.21% |
Recent News & Updates
GNI Group Ltd. (TSE:2160) Might Not Be As Mispriced As It Looks After Plunging 28%
Apr 11
GNI Group's (TSE:2160) Weak Earnings May Only Reveal A Part Of The Whole Picture
Feb 26Recent updates
GNI Group Ltd. (TSE:2160) Might Not Be As Mispriced As It Looks After Plunging 28%
Apr 11GNI Group's (TSE:2160) Weak Earnings May Only Reveal A Part Of The Whole Picture
Feb 26GNI Group Ltd.'s (TSE:2160) Shares Leap 25% Yet They're Still Not Telling The Full Story
Feb 21GNI Group Ltd. Just Missed Earnings - But Analysts Have Updated Their Models
Feb 18After Leaping 48% GNI Group Ltd. (TSE:2160) Shares Are Not Flying Under The Radar
Sep 20GNI Group's (TSE:2160) Shareholders Should Assess Earnings With Caution
Aug 27GNI Group Ltd. (TSE:2160) Stock's 37% Dive Might Signal An Opportunity But It Requires Some Scrutiny
Aug 06Investors Continue Waiting On Sidelines For GNI Group Ltd. (TSE:2160)
Jun 20Is GNI Group (TSE:2160) Using Too Much Debt?
Apr 12News Flash: Analysts Just Made An Incredible Upgrade To Their GNI Group Ltd. (TSE:2160) Forecasts
Mar 19Further Upside For GNI Group Ltd. (TSE:2160) Shares Could Introduce Price Risks After 40% Bounce
Feb 28Shareholder Returns
| 2160 | JP Biotechs | JP Market | |
|---|---|---|---|
| 7D | 2.9% | -0.2% | 2.9% |
| 1Y | 1.4% | 19.2% | 1.7% |
Return vs Industry: 2160 underperformed the JP Biotechs industry which returned 18.4% over the past year.
Return vs Market: 2160 matched the JP Market which returned 1% over the past year.
Price Volatility
| 2160 volatility | |
|---|---|
| 2160 Average Weekly Movement | 13.3% |
| Biotechs Industry Average Movement | 10.1% |
| Market Average Movement | 5.5% |
| 10% most volatile stocks in JP Market | 9.4% |
| 10% least volatile stocks in JP Market | 3.1% |
Stable Share Price: 2160's share price has been volatile over the past 3 months compared to the JP market.
Volatility Over Time: 2160's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of JP stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2001 | 867 | Ying Luo | www.gnipharma.com |
GNI Group Ltd. engages in the research, development, manufacture, and sale of pharmaceutical drugs in Japan and internationally. The company offers Etuary for the treatment of idiopathic pulmonary fibrosis. It also developing Etuary, which is in Phase III clinical trial for the treatment of connective tissue associated interstitial lung disease; and in clinical trial pre-phase III clinical trial pilot study for the treatment of radiation pneumonitis, as well as for the treatment of diabetic nephropathy.
GNI Group Ltd. Fundamentals Summary
| 2160 fundamental statistics | |
|---|---|
| Market cap | JP¥124.83b |
| Earnings (TTM) | JP¥1.10b |
| Revenue (TTM) | JP¥23.61b |
113.7x
P/E Ratio5.3x
P/S RatioIs 2160 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 2160 income statement (TTM) | |
|---|---|
| Revenue | JP¥23.61b |
| Cost of Revenue | JP¥5.58b |
| Gross Profit | JP¥18.04b |
| Other Expenses | JP¥16.94b |
| Earnings | JP¥1.10b |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
May 15, 2025
| Earnings per share (EPS) | 21.87 |
| Gross Margin | 76.39% |
| Net Profit Margin | 4.65% |
| Debt/Equity Ratio | 15.5% |
How did 2160 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/13 05:53 |
| End of Day Share Price | 2025/05/13 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
GNI Group Ltd. is covered by 5 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Stephen Barker | Jefferies LLC |
| Yuriko Ishida | Mizuho Securities Co., Ltd. |
| Nia Dokova | Pelham Smithers Associates Ltd. |